Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur Respir J
Päätekijät: Glassberg, Marilyn K., Wijsenbeek, Marlies S., Gilberg, Frank, Petzinger, Ute, Kirchgaessler, Klaus-Uwe, Albera, Carlo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: European Respiratory Society 2019
Aiheet:
Agora
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://ncbi.nlm.nih.gov/pubmed/31164431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00399-2019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia